Evidence map›Paper›PMID 41074452›Full record

ArticleThe Australasian journal of dermatology2025

Sycosis Barbae Treated With Bimekizumab.

Matiar Madanchi, Riccardo Curatolo, Lorenzo S Pelloni, Hazem A Juratli

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Australasian journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matiar MadanchiDepartment of Dermatology, University Hospital Basel, Basel, Switzerland.ORCID https://orcid.org/0000-0001-8396-3977
Riccardo CuratoloDepartment of Dermatology, University Hospital Basel, Basel, Switzerland.
Lorenzo S PelloniDepartment of Dermatology, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Hazem A JuratliInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sycosis barbae (SB) is a chronic, potentially scarring alopecia that primarily affects the beard. We report a unique case of refractory SB in a 31-year-old male successfully treated with bimekizumab, a dual inhibitor of interleukin (IL)-17A and IL-17F. Significant clinical improvement was observed after the second injection, with complete remission achieved after 4 months, highlighting the potential of this novel therapeutic approach for SB.

Indexed as

AlopeciaAntibodies, Monoclonal, HumanizedDermatologic AgentsAdultHumansInterleukin-17MaleAntibodies, Monoclonal, HumanizedDermatologic AgentsInterleukin-17

Identifiers

PMID41074452
PMCPMC12687684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.